Medical oncologists continue to face significant issues in obtaining full payment for and coverage of their services by third-party payers.
A number of issues raised by the Medicare fee schedule have, however, been at least partially resolved in a favorable manner.
There continue to be problems in coverage of off-label drug uses and services associated with clinical trials.
The impending reform of the health care system may improve the situation or it may give rise to further difficulties.
Mots-clés Pascal : Paiement, Honoraires, Médecin, Assurance maladie, Analyse coût, Chimiothérapie, Traitement, Homme, Pauvreté, Essai clinique, Tumeur maligne, Glande mammaire, Glande mammaire pathologie, Economie santé, Système santé, Etats Unis, Amérique du Nord, Amérique, Remboursement, Medicare
Mots-clés Pascal anglais : Payment, Fees, Physician, Health insurance, Cost analysis, Chemotherapy, Treatment, Human, Poverty, Clinical trial, Malignant tumor, Mammary gland, Mammary gland diseases, Health economy, Health system, United States, North America, America
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 93-0488424
Code Inist : 002B30A01B. Création : 199406.